The trial failed to demonstrate virtually any significant difference between the ECF and 5-FU hands for mOS (HR, One.Drive; 95% CI, 3.80-1.34; p?=?0.7) or perhaps 3-yr DFS (52 compared to. 50% correspondingly). Counter-intuitively, the toxic body comparison relating to the 5-FU supply when compared to ECF supply revealed a slightly greater therapy linked mortality (3% compared to.